NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

Core Insights - NurExone Biologic Inc. announced promising preclinical results for its lead candidate ExoPTEN, demonstrating a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma [1][2] Company Developments - The study was conducted in collaboration with the Goldschleger Eye Institute at Sheba Medical Center, showing that ExoPTEN's biological activity increases with higher dosing levels, leading to measurable recovery of visual function in animals with optic nerve injury [2][4] - Prof. Michael Belkin confirmed the potential of ExoPTEN to repair damaged optic nerves, which is crucial for addressing vision loss in patients with conditions like glaucoma [3] - Dr. Tali Kizhner highlighted the significance of the dose-response data as a step towards future clinical trials, emphasizing the dual action of exosomes and siRNA in promoting regeneration [3][4] Research Findings - The optic nerve crush model used in the experiments mimics glaucoma-related nerve damage, with both low and high doses of ExoPTEN showing improved visual signal strength in treated animals [4][5] - High-dose ExoPTEN treatment resulted in response amplitudes comparable to uninjured eyes, indicating substantial functional recovery [5][7] - The study's results align with previous findings from June and December 2024, which demonstrated structural preservation and survival of retinal ganglion cells [2][6] Financial and Corporate Actions - The company is accelerating the expiration date of certain warrants, which could yield approximately C$3.2 million if exercised, to be used for general corporate and working capital purposes [11][12] - The acceleration was triggered by the company's common shares trading above specified thresholds for 20 consecutive days [13] - The agreement with POSITIVE Communications has been extended to July 10, 2026, with additional financial terms [16][17] Market Position - NurExone focuses on developing exosome-based regenerative therapies for central nervous system injuries, with ExoPTEN showing strong preclinical data for treating acute spinal cord and optic nerve injuries, both representing multi-billion-dollar markets [18]